Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Enliven Therapeutics, Inc. (IMRA)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Jun-05-23 | Mar-31-23 | Jun-30-22 | Jun-05-22 | Mar-31-22 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 8-K | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-Q |
| Revenues | 0.0 | 15.2 | 0.0 | 0.0 | 7.9 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | 91.3% | | | | | | |
| Cost of goods sold | 0.0 | 20.1 | 0.0 | 0.0 | 9.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -5.0 | 0.0 | 0.0 | -1.1 | 0.0 | 0.0 | 0.0 |
| Gross margin | | -32.6% | | | -13.6% | | | |
| Selling, general and administrative [+] | 20.1 | 5.0 | 16.4 | 9.0 | 1.1 | 8.7 | 3.3 | 3.1 |
| General and administrative | | 5.0 | | | 1.1 | | 3.3 | 3.1 |
| Research and development | | | | | | | 10.4 | 10.1 |
| Other operating expenses | -6.8 | 10.2 | -3.4 | -0.3 | 6.9 | 0.0 | | |
| EBITDA [+] | -80.2 | | 54.0 | -47.7 | | 30.3 | -13.6 | -13.1 |
| EBITDA growth | 68.2% | 123.3% | 77.9% | 262.7% | | -395.9% | 9.4% | 27.9% |
| EBITDA margin | | -132.6% | | | -113.6% | | | |
| Depreciation and amortization | -66.9 | | 67.0 | -38.9 | | 39.0 | 0.0 | 0.0 |
| EBIT [+] | -13.3 | -20.1 | -13.0 | -8.8 | -9.0 | -8.7 | -13.7 | -13.2 |
| EBIT growth | 51.9% | 123.3% | 50.5% | -33.5% | | -15.8% | 9.3% | 27.8% |
| EBIT margin | | -132.6% | | | -113.6% | | | |
| Interest income | | | | | | | 0.0 | 0.0 |
| Interest income | | | | | | | 0.0 | 0.0 |
| Other income (expense), net [+] | -3.4 | 20.1 | -1.7 | -0.1 | 9.0 | 0.0 | 0.0 | 0.0 |
| Other | | | | | | | 0.0 | 0.0 |
| Pre-tax income | -16.7 | 0.0 | -14.7 | -8.9 | 0.0 | -8.7 | -13.6 | -13.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% |
| Net income | -16.7 | 0.0 | -14.7 | -8.9 | 0.0 | -8.7 | -13.6 | -13.2 |
| Net margin | | 0.0% | | | 0.0% | | | |
| |
| Basic EPS [+] | ($0.41) | $0.00 | ($0.80) | ($2.86) | $0.00 | ($3.01) | ($0.55) | ($0.74) |
| Growth | -85.7% | | -73.6% | 285.5% | | 416.4% | -23.5% | 25.2% |
| Diluted EPS [+] | ($0.41) | $0.00 | ($0.80) | ($2.86) | $0.00 | ($3.01) | ($0.55) | ($0.74) |
| Growth | -85.7% | | -73.6% | 285.5% | | 416.4% | -23.5% | 25.2% |
| |
| Shares outstanding (basic) [+] | 41.0 | 41.0 | 18.5 | 3.1 | 3.1 | 2.9 | 24.9 | 17.7 |
| Growth | 1219.6% | 1219.6% | 543.6% | -82.5% | | -83.6% | 43.5% | 3.0% |
| Shares outstanding (diluted) [+] | 41.0 | 41.0 | 18.5 | 3.1 | 3.1 | 2.9 | 24.9 | 17.7 |
| Growth | 1219.6% | 1219.6% | 543.6% | -82.5% | | -83.6% | 43.5% | 3.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|